Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Endometriosis: diagnosis and management

NICE guideline
Reference number: NG73
Published: 06 September 2017
Last updated: 11 November 2024

History

Guidance published

Equality impact assessment - Final (PDF 193 KB)

Published:

11 November 2024
Consultation comments and responses (PDF 863 KB)

Published:

11 November 2024
Committee member list (PDF 146 KB)

Published:

11 November 2024

Stakeholder list updated

Stakeholder list (PDF 45 KB)

Published:

08 November 2024

Declaration of interests

Register of interests (PDF 990 KB)

Published:

08 November 2024

Committee meetings

Committee meeting
Minutes 1 (PDF 253 KB)

Published:

06 March 2023
Minutes 2 (PDF 353 KB)

Published:

09 May 2023
Minutes 3 (PDF 258 KB)

Published:

27 November 2023
Minutes 4 (PDF 172 KB)

Published:

27 February 2024
Minutes 5 (PDF 203 KB)

Published:

21 May 2024
Minutes 6 (PDF 315 KB)

Published:

24 September 2024

Committee list updated

Committee member list (PDF 171 KB)

Published:

04 June 2024

Draft guidance consultation

Draft guidance consultation
Draft guideline (PDF version) (PDF 263 KB)

Published:

15 March 2024
Evidence review (PDF 3.62 MB)

Published:

15 March 2024
Equality impact assessment (PDF 144 KB)

Published:

15 March 2024
Comments form (MSWord 40 KB)

Published:

15 March 2024

Scope published

Final scope (PDF 200 KB)

Published:

14 July 2023

Update on 16 April 2024

Guidance published
Consultation comments and responses (PDF 480 KB)

Published:

16 April 2024
Equality impact assessment (PDF 177 KB)

Published:

16 April 2024
Committee member list (PDF 174 KB)

Published:

16 April 2024
Stakeholder list updated
Stakeholder list (PDF 151 KB)

Published:

15 April 2024
Draft guidance consultation
Draft guidance consultation
Draft guideline (PDF version) (PDF 163 KB)

Published:

08 February 2024
Comments form (MSWord 41 KB)

Published:

08 February 2024
Equality impact assessment (PDF Version) (PDF 145 KB)

Published:

08 February 2024
Evidence review (PDF 2.95 MB)

Published:

08 February 2024
Declaration of interests
Register of interests (PDF 1.22 MB)

Published:

09 January 2024
Scope published
Final scope (PDF 200 KB)

Published:

14 July 2023
Committee meeting
Minutes 1 (PDF 253 KB)

Published:

06 March 2023
Minutes 2 (PDF 353 KB)

Published:

09 May 2023
Minutes 3 (PDF 258 KB)

Published:

27 November 2023

Original development on 06 September 2017

Expected publication
Consultation comments and responses (PDF 2.27 MB)

Published:

06 September 2017
Equality impact assessment (PDF 162 KB)

Published:

06 September 2017
List of declarations of interest (PDF 978 KB)

Published:

06 September 2017
Stakeholder list updated
Stakeholder list (PDF 43 KB)

Published:

13 June 2017
Draft guidance consultation
Draft guidance consultation
Guideline appendix G (PDF 4.23 MB)

Published:

09 March 2017
Guideline appendix K (PDF 1.83 MB)

Published:

09 March 2017
Guideline appendix L (PDF 1.26 MB)

Published:

09 March 2017
Draft guideline (PDF 5.26 MB)

Published:

09 March 2017
Short version of draft guideline (PDF 464 KB)

Published:

09 March 2017
Equality impact assessment (PDF 160 KB)

Published:

09 March 2017
Comments form (MSWord 63 KB)

Published:

09 March 2017
Guideline appendices A, B, C (PDF 620 KB)

Published:

09 March 2017
Guideline appendices D, F, H - J (PDF 5.82 MB)

Published:

09 March 2017
Guideline appendix E (PDF 2.36 MB)

Published:

09 March 2017
Pre-consultation documents released
Search strategies (PDF 4.91 MB)

Published:

20 January 2017
Review questions (PDF 155 KB)

Published:

20 January 2017
Economic plan (PDF 150 KB)

Published:

20 January 2017
Committee meeting
Minutes 1 Day 1 (PDF 146 KB)

Published:

31 March 2016
Minutes 1 Day 2 (PDF 109 KB)

Published:

31 March 2016
Minutes 2 (PDF 108 KB)

Published:

31 March 2016
Minutes 3 (PDF 108 KB)

Published:

31 March 2016
Minutes 4 (PDF 111 KB)

Published:

31 March 2016
Minutes 5 (PDF 130 KB)

Published:

31 March 2016
Endometriosis: committee membership
Endometriosis: committee membership (PDF 11 KB)

Published:

02 July 2015
Endometriosis: equality impact assessment- scoping
Endometriosis: equality impact assessment- scoping (PDF 86 KB)

Published:

02 July 2015
Endometriosis: the scope
Endometriosis: the scope
Endometriosis: scope consultation comments and responses (PDF 416 KB)

Published:

02 July 2015
Endometriosis: final scope (PDF 180 KB)

Published:

02 July 2015
Endometriosis: consultation on the draft scope information
Endometriosis: draft scope (PDF 171 KB)

Published:

20 March 2015
Endometriosis: stakeholder workshop notes (PDF 155 KB)

Published:

18 March 2015
Endometriosis: registered list of stakeholders
Endometriosis: registered list of stakeholders (PDF 23 KB)

Published:

09 June 2015